Highlights
- Actinogen Medical (ASX:ACW) is developing Xanamem for cognitive decline and neurological conditions.
- The company’s lead programme is focused on Alzheimer’s disease.
- The XanaMIA study is a key clinical milestone.
- The company continues advancing additional research programmes.
- Clinical outcomes, funding and development progress remain key areas to monitor.
Actinogen Medical (ASX:ACW) is an Australian biotechnology company focused on developing treatments for neurological and cognitive disorders. The company’s lead asset, Xanamem, is being evaluated through clinical programmes designed to assess its potential in conditions associated with cognitive decline.
Company Overview
Actinogen Medical is developing Xanamem, also known as emestedastat, an oral therapeutic candidate designed to inhibit the 11 beta-HSD1 enzyme.
The company’s development approach is based on the Cortisol Hypothesis, which explores the relationship between elevated cortisol levels and cognitive decline.
Actinogen’s lead programme is XanaMIA, a clinical study evaluating Xanamem in Alzheimer’s disease.
The company is also exploring potential applications in major depressive disorder and Fragile X syndrome.
The company’s official information highlights its focus on developing therapies for neurological and cognitive disorders.
Clinical Development
XanaMIA is a Phase 2b/3 clinical study evaluating Xanamem in mild to moderate Alzheimer’s disease.
The study is designed to assess treatment outcomes over the clinical trial period.
The company has continued progressing clinical activities and monitoring trial development milestones.
Research Programmes
Beyond Alzheimer’s disease, Actinogen is assessing Xanamem across additional neurological and behavioural indications.
The company continues evaluating opportunities to expand understanding of the therapeutic candidate.
Future clinical outcomes will be important in determining the next stage of development.
Risks and Considerations
Biotechnology development involves clinical, regulatory and commercialisation risks.
Clinical trial outcomes may differ from expectations and determine future development pathways.
The company remains dependent on funding to continue Research and Development activities.
Key Insights
Actinogen Medical (ASX:ACW) is progressing Xanamem through clinical development programmes targeting neurological conditions. Future progress will depend on clinical outcomes, regulatory pathways, funding and successful advancement of its therapeutic platform.


_11_13_2026_02_22_23_205137.jpg)



Please wait processing your request...